Table 5. Hazard ratios (95% confidence intervals) for biochemical relapse after prostatectomy for established risk factors and nuclear ELAC2 expression in the ERG negative and positive subset.
| Model | Scenario 1 | Scenario 4 | |||
|---|---|---|---|---|---|
| ERG subset | Positive | Negative | Positive | Negative | |
| Variable | Category (N) | 3 291 | 4 033 | 3 301 | 4 141 |
| Gleason grade biopsy | ≥4+4 vs. 4+3 vs. 3+4 vs. ≤3+3 | 5.05 (4.08–6.23)*** | 3.51 (2.94–4.19)*** | ||
| cT stage | T2c vs. T1c | 2.23 (1.62–3.00)*** | 2.03 1.36–2.91)** | ||
| Preoperative PSA level | ≥20 vs. 11–20 vs. 4–10 vs.<4 | 4.22 (3.11–5.77)*** | 3.17 (2.39–4.25)*** | 1.87 (1.38–2.55)*** | 1.70 (1.29–2.28)** |
| Nuclear ELAC2 expression | Strong vs. mod. vs. weak vs. neg. | 1.42 (1.13–1.79)* | 1.67 (1.33–2.08)*** | 1.18 (0.94–1.48) | 1.43 (1.14–1.77)* |
| Gleason grade prostatectomy | ≥4+4 vs. 4+3 vs. 3+4 vs. ≤3+3 | 7.56 (5.27–10.9)*** | 4.84 (3.57–6.58)*** | ||
| pT stage | T4 vs. T3 vs. T2 | 3.03 (2.45–3.73)*** | 2.66 (2.21–3.20)*** | ||
| Surgical margin status | R1 vs. R0 | 1.49 (1.28–1.72)*** | 1.21 (1.05–1.39)*** | ||
| Nodal stage | N+ vs. N0 | 1.29 (1.04–1.60)* | 1.49 (1.21–1.82)** |
* p ≤ 0.05, ** p ≤ 0.001, *** p ≤ 0.0001.